Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Paper
  • Published:

Genetic disruption of host interferon-γ drastically enhances the metastasis of pancreatic adenocarcinoma through impaired expression of inducible nitric oxide synthase

Abstract

Synergistic induction of the inducible nitric oxide synthase (NOS II) gene requires a combination of interferon-γ (IFN-γ) and lipopolysaccharide (LPS). In this study, we determined whether the induction of IFN-γ was required for NOS II-mediated antitumor activity in vivo. Highly metastatic H7 murine pancreatic adenocarcinoma cells were implanted into the subcutis, footpad, and pancreas of syngeneic IFN+/+ and IFN-γ−/− mice. These cells grew and produced metastases and ascites in IFN-γ+/+ mice. In sharp contrast, the same tumor cells grew much more aggressively, metastasized more extensively, and produced a larger amount of malignant ascites in IFN-γ−/− mice. Also, induction of IFN-γ correlated with NOS II gene expression and NO production in IFN-γ+/+ injected with the tumor cells but not in IFN-γ−/− mice or IFN-γ+/+ mice without tumor challenge. In vitro, only LPS plus IFN-γ induced a high level of NO production and cytotoxicity against H7 cells. These data suggested that the tumor cells stimulated IFN-γ secretion from host cells, which in turn stimulated NO production by host cells and suppressed tumor growth and metastasis.

This is a preview of subscription content, access via your institution

Access options

Buy this article

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5

Similar content being viewed by others

References

  • Ambs S, Hussain SP, Harris CC . 1997 FASEB J. 11: 443–448

  • Chinje EC, Stratford IJ . 1997 Essays Biochem. 32: 61–72

  • Corbett TH, Roberts BJ, Leopold WR, Peckham JC, Wilkoff LJ, Groswold DP, Schabel Jr FM . 1984 Cancer Res. 44: 717–726

  • Einhorn S, Grander D . 1996 Interferon Cytokine Res. 16: 275–281

  • Farrar MA, Schreiber RD . 1993 Annu. Rev. Immunol. 11: 571–611

  • Gutterman JU . 1994 Proc. Natl. Acad. Sci. USA 91: 1198– 1205

  • Ignarro LJ, Buga GM, Wood KS, Byrns RE, Chaudhuri G . 1987 Proc. Natl. Acad. Sci. USA 84: 9265–9269

  • Jaffrey SR, Snyder SH . 1995 Annu. Rev. Cell Dev. Biol. 11: 417–440

  • Johns TG, Mackay IR, Callister KA, Hertzog PJ, Devenish RJ, Linnane AW . 1992 J. Natl. Cancer. Inst. 84: 1185– 1190

  • Kaplan D, Shankaran V, Dighe AS, Stockert E, Aguet M, Old LJ, Schreiber RD . 1998 Proc. Natl. Acad. Sci. USA 95: 7556–7561

  • Krown SE . 1988 J. Natl. Cancer Inst. 80: 306–309

  • Kundu N, Dorsey R, Jackson MJ, Guiterrez P, Wilson K, Fu S, Ramanujam K, Thomas E, Fulton AM . 1998 Int. J. Cancer 76: 713–719

  • Lokshin A, Mayotte, JE, Levitt ML . 1995 J. Natl. Cancer Inst. 87: 206–212

  • Moncada S, Higgs AN . 1993 N. Engl. J. Med. 329: 2002– 2012

  • Nathan C . 1992 FASEB J. 6: 3051–3064

  • Onier N, Hilpert S, Reveneau S, Arnould L, Saint-Giorgio V, Exbrayat JM, Jeannin JF . 1999 Int. J. Cancer 81: 755–760

  • Pestka S, Langer JA, Zoon KC, Samuel CE . 1987 Annu. Rev. Biochem. 56: 727–777

  • Schmidt HH, Walter U . 1994 Cell 78: 919–925

  • Shi Q, Huang S, Jiang W, Kutach LS, Ananthaswamy HM, Xie K . 1999 Cancer Res. 59: 2072– 2075

  • Shi Q, Wang B, Xiong Q, Le X, Khan N, Xie K . 2000 Cancer Res. 60: 2645– 2650

  • Shi Q, Xie K . 2000 Int. J. Oncol. 17: 217–225

  • Tannenbaum CS, Hamilton TA . 2000 Semin. Cancer Biol. 10: 113–123

  • Thomas H, Balkwill FR . 1991 Pharmacol. Ther. 52: 307–330

  • Tozer GM, Everett SA . 1997 Clin. Oncol. (R. Coll. Radiol.) 9: 357–364

  • Wang B, Xiong Q, Shi Q, Le X, Abbruzzese JL, Xie K . 2001a Cancer Res. 61: 71–75

  • Wang B, Xiong Q, Shi Q, Tan D, Le X, Xie K . 2001b Int. J. Cancer 91: 607–611

  • Wink DA, Vodovotz Y, Laval J, Laval F, Dewhirst MW, Mitchell JB . 1998 Carcinogenesis 19: 711–721

  • Xie K, Bielenberg D, Huang S, Juang S-H, Dong Z, Fidler IJ . 1997 Clin. Cancer Res. 3: 2189– 2199

  • Xie K, Fidler IJ . 1998 Cancer Metastasis Rev. 17: 55–75

  • Xie K, Huang X, Dong Z, Gutman M, Fidler IJ . 1995 Cancer Res. 55: 3123–3131

  • Zhang JF, Hu C, Geng Y, Selm J, Klein SB, Orazi A, Taylor MW . 1996 Proc. Natl. Acad. Sci. USA 93: 4513–4518

Download references

Acknowledgements

We thank Dr Suyun Huang for expert suggestion, Don Norwood for editorial comments, and Judy King for assistance in the preparation of this manuscript. This work was supported by the Lustgarten Pancreatic Cancer Research Foundation, the Research Project Grant #RPG-00-054-01-CMS from the American Cancer Society, and the Cancer Center Support Core Grant CA 16672-23 from the National Cancer Institute, National Institutes of Health (to K Xie).

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Keping Xie.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Wang, B., Xiong, Q., Shi, Q. et al. Genetic disruption of host interferon-γ drastically enhances the metastasis of pancreatic adenocarcinoma through impaired expression of inducible nitric oxide synthase. Oncogene 20, 6930–6937 (2001). https://doi.org/10.1038/sj.onc.1204871

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.onc.1204871

Keywords

This article is cited by

Search

Quick links